<DOC>
	<DOCNO>NCT00716066</DOCNO>
	<brief_summary>This phase II trial study side effect well carmustine , etoposide , cytarabine melphalan together antithymocyte globulin peripheral blood stem cell transplant work treat patient autoimmune neurologic disease respond previous therapy . In autoimmune neurological disease , patient 's immune system 'attacks ' nervous system might include brain/spinal cord and/or peripheral nerve . Giving high-dose chemotherapy , include carmustine , etoposide , cytarabine , melphalan , antithymocyte globulin , peripheral blood stem cell transplant weaken immune system may help stop immune system 'attacking ' patient 's nervous system . When patient 's ( autologous ) stem cell infuse patient help bone marrow make red blood cell , white blood cell , platelet blood count improve .</brief_summary>
	<brief_title>Carmustine , Etoposide , Cytarabine , Melphalan , Antithymocyte Globulin Followed Peripheral Blood Stem Cell Transplant Treating Patients With Autoimmune Neurologic Disease That Did Not Respond Previous Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate safety high-dose carmustine , etoposide , Ara-c ( cytarabine ) melphalan ( BEAM ) Thymoglobulin ( antithymocyte globulin ) high-dose immunosuppressive treatment ( HDIT ) regimen patient severe , refractory neurological autoimmune disease . SECONDARY OBJECTIVES : I . Evaluate disease response duration response HDIT autologous hematopoietic stem cell transplantation ( HSCT ) . II . Determine efficacy safety G-CSF ( filgrastim ) prednisone cyclophosphamide hematopoietic stem mobilization patient neurological autoimmune disease . OUTLINE : Patients receive carmustine intravenously ( IV ) day -6 , etoposide IV cytarabine IV twice daily ( BID ) day -5 -2 , melphalan IV day -1 , antithymocyte globulin IV day -2 -1 . Patients undergo autologous syngeneic peripheral blood stem cell transplant day 0 . Patients also receive prednisone orally ( PO ) daily ( QD ) day 7-21 , follow 2 week taper . After completion study treatment , patient follow 3 month , 1 year , annually thereafter 5 year .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patients autoimmune disorder central peripheral nervous system eligible ; include : Primary Central Nervous System ( CNS ) vasculitis Rasmussen 's encephalitis Autoimmune peripheral neuropathy ( antiHu [ Anna1 ] , antiGM1 [ GD1b ] , antiMAG , antiganglioside , antisulfatide ) Autoimmune cerebellar degeneration Gait Ataxia Late age Onset Polyneuropathy ( GALOP ) Stiff Person Syndrome Chronic Inflammatory Demyelinating Polyneuropathy Myasthenia Gravis LambertEaton myasthenic syndrome Human Tcell lymphotropic virus ( HTLV ) 1associated myelopathy ( HAM ) / tropical spastic paraparesis ( TSP ) Opsoclonus / myoclonus ( antiRi ) Neuromyelitis optica Multiple sclerosis ( Only patient relapsing/remitting MS include . ) Other central peripheral nervous system autoimmune disease approve study neurologist Fred Hutchinson Cancer Research Center ( FHCRC ) faculty Patient Care Conference ( PCC ) Patients must satisfy criterion diagnosis one severe neurological autoimmune disorder outline Evidence disease activity outline ( e.g . gadolinium enhancement magnetic resonance image brain clinical progression ) Patients must fail least 2 line stand therapy outline specific disease DONOR : Sibling patient enrol protocol proven ABO typing , human leukocyte antigen ( HLA ) type variable number tandem repeat ( VNTR ) analysis syngeneic patient ( e.g . identical twin ) DONOR : Willing undergo multiple apheresis procedure ( except donor &lt; 12 year undergo bone marrow harvest ) Pregnancy express plan become pregnant within 1 year procedure Patients serologically positive human immunodeficiency virus ( HIV ) Patients pulmonary , cardiac , hepatic renal impairment would limit ability receive cytoreductive therapy compromise survival ; include patient follow : Severe pulmonary dysfunction associate carbon monoxide diffuse capacity ( DLCO ) ( correct hemoglobin ) &lt; 60 % , require supplemental oxygen Uncontrolled malignant arrhythmia , clinical evidence congestive heart failure ( New York class IIIIV ) ejection fraction &lt; 50 % Renal disease estimate glomerular filtration rate ( GFR ) creatinine clearance iothalamate clearance &lt; 50 ml/min/1.73 m^2 body surface area Serum glutamate pyruvate transaminase ( SGPT ) /aspartate aminotransferase ( AST ) &gt; 3 time normal direct bilirubin great 2.5 mg/dL two repeat test Active uncontrolled infection Demonstrated lack compliance prior medical care Patients whose life expectancy limit illness neurological condition Patients evidence myelodysplasia Active malignancy ( exclude localize squamous cell basal cell carcinoma skin ) DONOR : Inadequate documentation donor recipient syngeneic DONOR : Donors fulfill criterion apheresis donor establish institutional guideline DONOR : Concordant autoimmune neurological disease ( ) determine neurological evaluation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>